GlobeNewswire Inc | Sep 10, 2020 09:00AM EDT

September 10, 2020

BOSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences:

H.C. Wainwright 22nd Annual Global Investment ConferenceDate: Wednesday, September 16, 2020Time: 9:00 a.m. ET (presentation)

Cantor Virtual Global Healthcare ConferenceDate: Thursday, September 17, 2020Time: 1:20 p.m. ET (fireside chat)

To access the live webcast presentations, or the subsequent archived recordings, please visit the Investors section of the Ziopharm website at www.ziopharm.com.

AboutZiopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viralSleeping Beautygene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufacturedSleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with theNational Cancer Institute,The University of Texas MD Anderson Cancer Centerand others. For more information, please visitwww.ziopharm.com.

Investor Relations Contacts: Ziopharm Oncology: Chris Taylor VP, Investor Relations and Corporate Communications T: 617.502.1881 E:ctaylor@ziopharm.com

LifeSci Advisors: Mike Moyer Managing Director T: 617.308.4306 E:mmoyer@lifesciadvisors.com

Media Relations Contact: LifeSci Communications: Patrick Bursey T: 646.876.4932 E:pbursey@lifescicomms.com